Neuromyelitis Optica Spectrum Disorder as an Initial Presentation of Primary Sjögren's Syndrome

Seminars in Arthritis and Rheumatism

Volumn 40, Issue 4, 2011, Pages 343-348

  Kahlenberg, J Michelle ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Aquaporin 4; Devic's disease; Myelitis; Neuromyelitis optica; NMO; Sjogren's syndrome

Indexed keywords

ANTINUCLEAR ANTIBODY; AQUAPORIN 4; AZATHIOPRINE; CARBAMAZEPINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G ANTIBODY; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; RO ANTIBODY;

ADULT; AFRICAN AMERICAN; ANTIBODY TITER; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG SUBSTITUTION; EMBASE; FEMALE; HOSPITAL ADMISSION; HUMAN; LYMPHOCYTIC INFILTRATION; MEDLINE; MOLECULAR MECHANICS; MULTIPLE CYCLE TREATMENT; MYELITIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; SALIVARY GLAND BIOPSY; SJOEGREN SYNDROME;

AQUAPORIN 4; AUTOANTIBODIES; FEMALE; HUMANS; MIDDLE AGED; NEUROMYELITIS OPTICA; SJOGREN'S SYNDROME;

EID: 78751701078     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2010.05.005     Document Type: Article

References (38)

1. Ozgocmen S., Gur A. Treatment of central nervous system involvement associated with primary Sjögren's syndrome. Curr Pharm Des 2008, 14(13):1270-1273.
2. Morgen K., McFarland H.F., Pillemer S.R. Central nervous system disease in primary Sjögren's syndrome: the role of magnetic resonance imaging. Semin Arthritis Rheum 2004, 34(3):623-630.
3. Theodoridou A., Settas L. Demyelination in rheumatic diseases. Postgrad Med J 2008, 84(989):127-132.
4. Sa M.J. Acute transverse myelitis: A practical reappraisal. Autoimmun Rev 2009, 9(2):128-131.
5. Weinshenker B.G., Wingerchuk D.M. Neuromyelitis optica: Clinical syndrome and the NMO-IgG autoantibody marker. Curr Top Microbiol Immunol 2008, 318:343-356.
6. Dalakas M.C. B cells in the pathophysiology of autoimmune neurological disorders: A credible therapeutic target. Pharmacol Ther 2006, 112(1):57-70.
7. Diamond B., Huerta P.T., Mina-Osorio P., Kowal C., Volpe B.T. Losing your nerves?. Maybe it's the antibodies. Nat Rev Immunol 2009, 9(6):449-456.
8. Roemer S.F., Parisi J.E., Lennon V.A., Benarroch E.E., Lassmann H., Bruck W., et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007, 130(Pt. 5):1194-1205.
9. Jarius S., Aboul-Enein F., Waters P., Kuenz B., Hauser A., Berger T., et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008, 131(Pt. 11):3072-3080.
10. Mochizuki A., Hayashi A., Hisahara S., Shoji S. Steroid-responsive Devic's variant in Sjögren's syndrome. Neurology 2000, 54(6):1391-1392.
11. Javed A., Balabanov R., Arnason B.G.W., Kelly T.J., Sweiss N.J., Pytel P., et al. Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler 2008, 14(6):809-814.
12. Brinar V.V., Habek M., Zadro I., Barun B., Ozretic D., Vranjes D. Current concepts in the diagnosis of transverse myelopathies. Clin Neurol Neurosurg 2008, 110(9):919-927.
13. Wandinger K.P., Stangel M., Witte T., Venables P., Charles P., Jarius S., et al. Autoantibodies against aquaporin-4 in patients with neuropsychiatric SLE and primary Sjögren's syndrome. Arthritis Rheum 2010, 62(4):1198-1200.
14. Wingerchuk D.M., Lennon V.A., Lucchinetti C.F., Pittock S.J., Weinshenker B.G. The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6(9):805-815.
15. Hamnik S.E., Hacein-Bey L., Biller J., Gruener G., Jay W. Neuromyelitis optica (NMO) antibody positivity in patients with transverse myelitis and no visual manifestations. Semin Ophthalmol 2008, 23(3):191-200.
16. Min J.H., Kim H.J., Kim B.J., Lee K.W., Sunwoo I.N., Kim S.M., et al. Brain abnormalities in Sjögren's syndrome with recurrent CNS manifestations: Association with neuromyelitis optica. Mult Scler 2009, 15(9):1069-1076.
17. Pittock S.J., Lennon V.A., de Seze J., Vermersch P., Homburger H.A., Wingerchuk D.M., et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008, 65(1):78-83.
18. Tristano A.G. A case of Sjögren's syndrome with acute transverse myelitis and polyneuropathy in a patient free of sicca symptoms. Clin Rheumatol 2006, 25(1):113-114.
19. Manabe Y., Sasaki C., Warita H., Hayashi T., Shiro Y., Sakai K., et al. Sjögren's syndrome with acute transverse myelopathy as the initial manifestation. J Neurol Sci 2000, 176(2):158-161.
20. Alhomoud I.A., Bohlega S.A., Alkawi M.Z., Alsemari A.M., Omer S.M., Alsenani F.M. Primary Sjögren's syndrome with central nervous system involvement. Saudi Med J 2009, 30(8):1067-1072.
21. Delalande S., de Seze J., Fauchais A.L., Hachulla E., Stojkovic T., Ferriby D., et al. Neurologic manifestations in primary Sjögren's syndrome: A study of 82 patients. Medicine 2004, 83(5):280-291. (Baltimore).
22. Gresz V., Kwon T.H., Hurley P.T., Varga G., Zelles T., Nielsen S., et al. Identification and localization of aquaporin water channels in human salivary glands. Am J Physiol Gastrointest Liver Physiol 2001, 281(1):G247-G254.
23. Cikes N., Bosnic D., Sentic M. Non-MS autoimmune demyelination. Clin Neurol Neurosurg 2008, 110(9):905-912.
24. Cree B.A., Lamb S., Morgan K., Chen A., Waubant E., Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005, 64(7):1270-1272.
25. Jacob A., Matiello M., Weinshenker B.G., Wingerchuk D.M., Lucchinetti C., Shuster E., et al. Treatment of neuromyelitis optica with mycophenolate mofetil: Retrospective analysis of 24 patients. Arch Neurol 2009, 66(9):1128-1133.
26. Konttinen Y.T., Kinnunen E., von Bonsdorff M., Lillqvist P., Immonen I., Bergroth V., et al. Acute transverse myelopathy successfully treated with plasmapheresis and prednisone in a patient with primary Sjögren's syndrome. Arthritis Rheum 1987, 30(3):339-344.
27. Alcântara C., Gomes M.J., Ferreira C. Rituximab therapy in primary Sjögren's syndrome. Ann NY Acad Sci 2009, 1173:701-705. (Contemporary Challenges in Autoimmunity).
28. Yamamoto T., Ito S., Hattori T. Acute longitudinal myelitis as the initial manifestation of Sjögren's syndrome. J Neurol Neurosurg Psychiatry 2006, 77(6). 780.
29. Quartuccio L., Ferraccioli G.F., De Vita S. Transverse myelitis in primary Sjögren's syndrome: Usefulness of low dose oral cyclophosphamide rather than pulse therapy. Scand J Rheumatol 2006, 35(5):409-410.
30. Kim S., Waters P., Vincent A., Kim S., Kim H., Hong Y., et al. Sjögren's syndrome myelopathy: Spinal cord involvement in Sjögren's syndrome might be a manifestation of neuromyelitis optica. Mult Scler 2009, 15(9):1062-1068.
31. Barroso B. Primary Sjögren's syndrome mimicking neuromyelitis optica. Eur J Int Med 2007, 18(6). 507.
32. Anantharaju A., Baluch M., Van Thiel D.H. Transverse myelitis occurring in association with primary biliary cirrhosis and Sjögren's syndrome. Dig Dis Sci 2003, 48(4):830-833.
33. Arabshahi B., Pollock A.N., Sherry D.D., Albert D.A., Kreiger P.A., Pessler F. Devic disease in a child with primary Sjögren's syndrome. J Child Neurol 2006, 21(4):285-286.
34. Hummers L.K., Krishnan C., Casciola-Rosen L., Rosen A., Morris S., Mahoney J.A., et al. Recurrent transverse myelitis associates with anti-Ro (SSA) autoantibodies. Neurology 2004, 62(1):147-149.
35. Wright R.A., O'Duffy J.D., Rodriguez M. Improvement of myelopathy in Sjögren's syndrome with chlorambucil and prednisone therapy. Neurology 1999, 52(2):386-388.
36. Williams C.S., Butler E., Roman G.C. Treatment of myelopathy in Sjögren's syndrome with a combination of prednisone and cyclophosphamide. Arch Neurol 2001, 58(5):815-819.
37. Hermisson M., Klein R., Schmidt F., Weller M., Küker W. Myelopathy in primary Sjögren's syndrome: diagnostic and therapeutic aspects. Acta Neurol Scand 2002, 105(6):450-453.
38. Vincent T.L., Richardson M.P., Mackworth-Young C.G., Hawke S.H., Venables P.J.W. Sjögren's syndrome-associated myelopathy: Response to immunosuppressive treatment. Am J Med 2003, 114(2):145-148.